Multilevel structure–activity profiling reveals multiple green tea compound families that each modulate ubiquitin-activating enzyme and ubiquitination by a distinct mechanism by Fenteany, Gabriel et al.
1Scientific RepoRtS |         (2019) 9:12801  | https://doi.org/10.1038/s41598-019-48888-6
www.nature.com/scientificreports
Multilevel structure–activity 
profiling reveals multiple green 
tea compound families that each 
modulate ubiquitin-activating 
enzyme and ubiquitination by a 
distinct mechanism
Gabriel Fenteany  1, paras Gaur1, Lili Hegedűs1, Kata Dudás1, Ernő Kiss1, Edit Wéber2, 
László Hackler3, Tamás Martinek2, László G. Puskás4,5 & Lajos Haracska1
We developed and implemented a reconstituted system to screen for modulators of the ubiquitination 
of proliferating cell nuclear antigen, a process that activates pathways of DNA damage tolerance 
and drug resistance. We identified the primary putatively health-beneficial green tea polyphenol 
epigallocatechin gallate (EGCG) and certain related small molecules as potent inhibitors of 
ubiquitination. EGCG directly and reversibly targets the ubiquitin-activating enzyme Uba1, blocking 
formation of the Uba1~ubiquitin thioester conjugate and thus ubiquitination and in the cell. Structure–
activity relationship profiles across multiple biochemical and cellular assays for a battery of EGCG 
analogues revealed distinct chemical and mechanism-of-action clusters of molecules, with catechin 
gallates, alkyl gallates, and myricetin potently inhibiting ubiquitination. This study defines a number of 
related though distinct first-in-class inhibitors of ubiquitination, each series with its own unique activity 
pattern and mechanistic signature.
Substantial compelling evidence suggests inhibition of the DNA repair and damage tolerance machinery is a 
viable strategy for the development of therapeutics against cancers and other diseases. We are interested in dis-
covering and leveraging small molecules that modulate the function of proteins involved in the DNA damage 
response as potential drug leads and research probes. Such agents would ideally limit the proliferation of and 
induce apoptotic death in diseased cells—either as standalone drugs or in synergistic combination with other 
treatments, such as chemotherapy, radiotherapy, and targeted therapies—and reverse loss of efficacy in cases of 
therapeutic resistance. The primary modes of DNA damage tolerance are the translesion synthesis and template 
switching pathways, which are engaged when replication forks stall at sites of unrepaired DNA damage and are 
unable to copy through the DNA (reviewed in1–4). These pathways involve transient changes in components of the 
replication machinery, allowing for replication past DNA lesions, though at a price: Translesion synthesis occurs 
through specialized polymerases that are inherently prone to error, whereas template switching can result in chro-
mosomal rearrangements. DNA damage tolerance can thus lead to heightened mutagenesis, genomic instability, 
oncogenesis, formation of secondary tumors in cancer patients after treatment with DNA-damaging therapeutics, 
intrinsic and acquired drug resistance, and other pathologies (reviewed in5–7).
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A principal activating step in DNA damage tolerance pathways is the modification of proliferating 
cell nuclear antigen (PCNA), a central replication and repair factor that forms a homotrimeric clamp 
encircling DNA, by covalent attachment of ubiquitin to PCNA. Ubiquitination of PCNA prerequires the 
ATP-dependent loading of PCNA onto DNA by replication factor C (RFC), which makes PCNA a competent 
substrate for efficient ubiquitination. The reaction cascade then proceeds via: (1) ATP-dependent activation 
of the carboxy terminus of ubiquitin catalyzed by the E1 ubiquitin-activating enzyme Uba1 (also known as 
UBE1) through formation of a ubiquitin adenylate intermediate that then reacts with the active-site cysteine 
on Uba1, yielding a high-energy Uba1~ubiquitin thioester intermediate; (2) transfer of the ubiquitin moiety 
to the catalytic cysteine on the E2 ubiquitin-conjugating enzyme Rad6 to form a Rad6~ubiquitin thioester 
intermediate; and (3) transfer of ubiquitin from Rad6 specifically to the side-chain amine of the K164 res-
idue on PCNA to form a PCNA–ubiquitin isopeptide bond, mediated by the E3 ubiquitin ligase Rad18 in 
complex with Rad6 (reviewed in1–4,8).
We seek to identify and exploit new small-molecule modulators of the PCNA ubiquitination cascade as poten-
tial therapeutics and research tools. Thus, we developed a robust, reliable, and sensitive high-throughput assay 
to quantitatively measure PCNA ubiquitination, based on amplified luminescent proximity homogeneous assay 
(Alpha) technology. The assay is reconstituted from all the individual purified proteins (RFC, Uba1, Rad6, Rad18, 
PCNA, and ubiquitin) that comprise the minimal necessary and sufficient components for the loading of PCNA 
onto DNA and its subsequent monoubiquitination. Over the course of screening a chemical library for com-
pounds that affect PCNA ubiquitination, we identified the flavonoid (−)-epigallocatechin-3-gallate (EGCG) as a 
potent inhibitor of the reaction cascade. EGCG is the main polyphenol in green tea and has numerous reported 
activities, with compelling potential in cancer prevention and treatment (having been shown in previous studies 
to inhibit cell growth, induce apoptosis, increase sensitivity to other cytotoxic agents, and mitigate drug resist-
ance), as well as in applications against various neurodegenerative, cardiovascular, immune, inflammatory, met-
abolic, microbial, and viral diseases (reviewed in9–30).
Investigating in further detail the mechanism of EGCG’s strong inhibition of PCNA ubiquitination, we 
determined that EGCG blocks formation of the Uba1~ubiquitin thioester conjugate and directly targets Uba1 
itself and not just secondarily to interaction or reaction with ubiquitin. Uba1 is required for the initial acti-
vation of ubiquitin for almost all ubiquitination events, with a consequently wide range of biological effects 
in normal and pathological states such as cancers and neurodegenerative diseases (reviewed in31–33). We eval-
uated the biological relevance of Uba1 as a genuine target of EGCG in the cell. We discovered that human 
embryonic kidney (HEK) 293 cells overexpressing Uba1 have reduced sensitivity to the cytostatic and cyto-
toxic effects of EGCG relative to control cells, implying that EGCG binds Uba1 in the cell with functional 
effects on cell viability. Through comparative evaluation of a panel of EGCG analogues across multiple assays 
to establish combined structure–activity relationship (SAR) profiles, we noticed distinct subclasses of mole-
cules, with clusters of different activity patterns that are clearly related to chemical features common to each 
grouping. In particular, three SAR clusters—catechin gallates, alkyl gallates, and myricetin—display inhibitory 
activity against PCNA ubiquitination and Uba1~ubiquitin thioester formation, and consistent cellular activity, 
though each with its own apparent mechanistic profile. Collectively, our results delineate pharmacophores that 
may serve in the potential development of more selective agents as tools for research and chemotherapeutics 
against cancers and other diseases.
Results
Development of a high-throughput reconstituted screening system to identify modulators of 
PCNA ubiquitination. We designed and implemented a quantitative high-throughput assay for PCNA ubiq-
uitination based on PerkinElmer’s AlphaScreen/AlphaLISA system (Fig. 1a), with wide dynamic range, and very 
strong signal in positive control relative to negative control (Fig. 1b), as also confirmed by Western blot analysis 
(Figs 1c and 2). We found the assay to be reliable, robust, and scalable. It consists of a reconstituted system con-
taining biotin-conjugated ubiquitin, FLAG-tagged PCNA, nicked circular pUC19 plasmid, RFC, Uba1, Rad6, and 
Rad18, adapted from a previously published assay34, with ubiquitination of PCNA by Rad6–Rad18 being specific 
for the K164 residue, as K164R mutant PCNA protein is not ubiquitinated34,35.
Compounds were transferred to plates and briefly incubated to ensure equilibrium binding, then ATP was 
added to initiate the PCNA loading and ubiquitination reaction cascades. After incubation, we stopped the reac-
tions by addition of EDTA to chelate Mg2+, diluted in buffer containing Alpha donor and acceptor beads, then 
loaded and read the plates in a microplate reader with attached stacker and dedicated laser for excitation of donor 
beads. We conducted each experiment in triplicate, with multiple positive and negative controls on each plate.
EGCG inhibits PCNA ubiquitination. We identified EGCG (structure in Fig. 6) as one of the bioactive 
hits from a pilot screen of ca. 6,400 compounds. Dose–response experiments revealed that EGCG inhibits PCNA 
ubiquitination in vitro (Fig. 2a,b) with a calculated half-maximal inhibitory concentration (IC50) of 228 nM 
(Table 1).
EGCG blocks Uba1~ubiquitin thioester formation. Inhibition of overall PCNA ubiquitination in our 
reconstituted system could be caused by direct inhibition of any of the components of the reaction sequence: 
Uba1, Rad6, Rad18, PCNA, or ubiquitin (or RFC, since loading of PCNA onto DNA is a requisite for its ubiq-
uitination). We therefore looked at specific steps in the cascade and found that EGCG inhibits formation of the 
Uba1~ubiquitin thioester adduct (Fig. 3a,b and Table 1) in an assay consisting only of Uba1, ubiquitin, and ATP. 
Furthermore, preincubation of Uba1 alone before adding ubiquitin and ATP resulted in complete inhibition, 
whereas preincubation of ubiquitin alone with EGCG prior to adding Uba1 and ATP did not (Fig. 3a).
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We conducted reversibility experiments by preincubating Uba1 or ubiquitin with EGCG and then washing 
out unbound compound by serial centrifugal filtration, followed by addition of other components to assay for 
ubiquitination. We found that ubiquitination activity recovers upon washout of compound, demonstrating that 
EGCG inhibits Uba1 and consequent ubiquitination in a reversible manner (Fig. 2d).
Nuclear magnetic resonance (NMR) shows that EGCG binds Uba1. The binding of EGCG to Uba1 was 
established by ligand-detected 1H NMR techniques. In the presence of Uba1, signal intensity loss was observed in the 
aromatic 1H NMR signals of EGCG compared with the control spectrum containing no protein (Fig. 4a), indicative of 
a dissociation constant (Kd) of low micromolar or less. The interaction was also tested by standard saturation transfer 
difference (STD) NMR36–38 and transferred nuclear Overhauser effect (trNOE) experiments. In the STD spectrum of 
EGCG, 1H signals of EGCG were clearly detected, demonstrating ligand binding to Uba1 (Fig. 4b). The interaction 
was also confirmed by trNOE NMR. In presence of Uba1, positive crosspeaks were observed due to the higher cross 
relaxation rates of EGCG upon protein binding (Fig. 4c). In the 2D NOESY spectrum of the EGCG control sample, no 
crosspeaks appeared. Both STD and trNOE requires dynamic equilibrium between the free and the bound states of the 
ligand and are sensitive in the Kd range of 10−3–10−8 M. As signal intensity loss of EGCG signals was also observed, the 
Figure 1. Reconstituted assay for PCNA ubiquitination. (a) High-throughput screening system for PCNA 
ubiquitination (FLAG-PCNA and biotin-ubiquitin proximity) in vitro, based on PerkinElmer’s AlphaScreen/
AlphaLISA technology.  Note: Unlike in this simplified diagram, each of the three subunits of the PCNA trimer 
bears a FLAG tag and each PCNA molecule is monoubiquitinated on K164 at saturation in the reaction; thus, 
higher bead-to-trimer stoichiometry will occur than indicated (in principle, three donor and three acceptor 
beads per complex, depending on steric factors). (b) Quantitative measurement of PCNA ubiquitination by the 
Alpha system for non-initiated (−ATP) and initiated (+ATP) ubiquitination reaction cascades. Data represent 
mean and standard deviation (SD) for six independent experiments for Alpha signal values in counts per 
second (cps) following incubation without or with ATP for 2 h, under conditions described in Methods. (c) 
Representative Western blot of samples incubated without or with ATP for 2 h probed with anti-FLAG antibody, 
as described in Methods, showing nonubiquitinated FLAG-PCNA (lower band) and ubiquitinated FLAG-
PCNA (upper band).
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Figure 2. Catechin gallates, alkyl gallates, and myricetin inhibit PCNA ubiquitination. (a) Representative 
Western blot probed with anti-FLAG antibody showing the dose–response for inhibition of PCNA 
ubiquitination by EGCG (0.0122 to 6.25 μM in concentration increments of 2×), with a final DMSO carrier 
solvent concentration of 2% in all cases. Samples were preincubated with EGCG for 15 min prior to addition 
of ATP, then further incubated for 2 h. Negative and positive controls consisted of parallel samples incubated 
with DMSO alone in the absence (−) or presence (+) of ATP, respectively. (b) Dose–response for % PCNA 
ubiquitination for the different compounds, plotted both linearly and semi-logarithmically (inset), with a 
DMSO concentration of 2% in all cases. Data represent mean ± SD, derived from quantitation of Western 
blot images according to (FLAG-PCNA–ubiquitin)/(FLAG-PCNA + FLAG-PCNA–ubiquitin) × 100% for 
each lane internally from 3–7 independent experiments, as indicated for each case in Table 1 along with IC50 
values. (c) % PCNA ubiquitination for compounds with no inhibitory activity even at 500 μM, with a DMSO 
concentration of 2% in all cases. Data represent mean and SD for three independent experiments. Negative 
and positive controls consisted of DMSO alone without or with ATP, respectively. (d) Effects of EGCG and 
Myr on Uba1 and ubiquitination are reversible. 30 μM EGCG or 30 μM Myr (with DMSO alone as control 
and a DMSO concentration of 2% in all cases) were preincubated with Uba1 for 2 h, completely washed out by 
serial centrifugal filtration, and then assayed for PCNA ubiquitination activity after addition of other reaction 
components, with detection by Western blot analysis with anti-FLAG antibody.
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NMR measurements suggest a Kd for the EGCG–Uba1 interaction in the high-nanomolar-to-low-micromolar range 
for a single binding mode.
Overexpression of Uba1 or ubiquitin protects cells from EGCG’s cytostatic/cytotoxic effects and 
EGCG inhibits global cellular ubiquitination. Treatment with EGCG reduces the viability and growth 
of HEK 293FT cells (Fig. 5a). Transfected HEK 293 cells overexpressing FLAG-tagged Uba1 or FLAG-tagged 
ubiquitin exhibited reduced sensitivity to EGCG compared to cells transfected with FLAG-tag-containing empty 
vector alone (Fig. 5b). In contrast, the unrelated cytotoxic compound puromycin displayed no differences in 
apparent toxic potency between normal and Uba1- or ubiquitin-overexpressing cells (Fig. 5b). Moreover, EGCG 
treatment inhibited the accumulation of ubiquitin-conjugated protein species in response to treatment with the 
peptide aldehyde proteasome inhibitor MG132 (Fig. 5c).
SAR with EGCG analogues reveals distinct groupings of congeners by structure, activity pro-
file, and mechanisms of action. We tested a series of EGCG-related molecules (structures in Fig. 6) for 
potential inhibitory activity in the same assays as before: PCNA ubiquitination in vitro (Fig. 2b,c), Uba1 charging 
with ubiquitin to form the Uba1~ubiquitin thioester adduct in vitro (Fig. 3b,c), and effects on the viability of HEK 
293 cells (empty vector-transfected control, Uba1-overexpressing, and ubiquitin-overexpressing; Fig. 5b). All of 
the compounds tested have molecular weights (170.120–458.375) and predicted logP values (0.72–5.95, calcu-
lated with the Consensus model implemented in ChemAxon MarvinSketch 19.2) that suggest no likely questions 
of low cell permeability.
The combined SAR results from Figs 2, 3 and 5 are summarized with structures in Fig. 6, with calculated IC50 
values for inhibition in the different assays presented in Table 1. EGCG was inhibitory in all the assays. The other 
catechin galloyl ester tested, (−)-epicatechin-3-gallate (ECG), was also active in all the assays (Figs 2b, 3b and 4a), 
and its inhibitory effect on cell viability was mitigated with overexpression of Uba1 or ubiquitin, as with EGCG 
(Fig. 5b). Of the unesterified catechins tested, (−)-epigallocatechin (EGC) displayed weak activity in the PCNA 
ubiquitination (Fig. 2b) and Uba1~ubiquitin thioester formation assays (Fig. 3b), while (−)-epicatechin (EC) and 
(+)-catechin (Cat) were inactive in both of these assays (Figs 2c and 3c). Unlike EC and Cat, EGC also has meas-
urable cytostatic/cytotoxic activity (Fig. 5a). However, EGC’s negative effect on cell survival was not affected by 
Uba1 or ubiquitin overexpression (Fig. 5b). Free gallic acid (GA) and n-propyl gallate (PG), a short straight-chain 
alkyl galloyl ester, were inactive in the PCNA ubiquitination (Fig. 2c) and Uba1~ubiquitin thioester formation 
assays (Fig. 3c) but had little effects on cell viability (Fig. 5a). What inhibitory activity was observed was not 
mitigated with Uba1 or ubiquitin overexpression (Fig. 5b). Longer linear alkyl galloyl esters—n-octyl gallate 
(OG) and n-dodecyl (lauryl) gallate (DG)—were active in all the assays (Figs 2b, 3b and 4a), and overexpression 
of Uba1 or ubiquitin protected cells from their negative effects on cell survival (Fig. 5b). Myricetin (Myr) and 
(+)-dihydromyricetin (DM; also known as ampelopsin) were active against PCNA ubiquitination (Fig. 2b) and 
Uba1~ubiquitin thioester formation (Fig. 3a,c) but only had very weak activity against cell survival (Fig. 5a), 
although cells were protected from even that weak cytostatic/cytotoxic activity by overexpression of Uba1 or 
ubiquitin (Fig. 5b).
The alkyl gallates inhibited PCNA ubiquitination and Uba1~ubiquitin thioester formation with a potency 
directly proportional to the length of their alkyl chains in the rank order: DG > OG ≫ PG (the last one 
more-or-less inactive); Myr and DM also inhibited PCNA ubiquitination and Uba1~ubiquitin thioester forma-
tion in the order: Myr ≫ DM (Figs 2, 3 and 5 and Table 1). However, with Myr, unlike with EGCG, preincubation 
of not only Uba1 alone but also ubiquitin alone prior to adding the other reaction components for thioester 
formation resulted in inhibition (Fig. 3a). Since the presence of a Michael acceptor functionality in Myr makes 
a mechanism involving a covalent reaction with the target, which often but not always is irreversible, we tested 
whether Myr irreversibly inhibits PCNA ubiquitination or not by determining if enzyme activity recovers after 
washing out of compound through serial centrifugal filtration. Myr’s inhibitory effects on PCNA ubiquitination, 
like EGCG’s, were reversible (Fig. 2d).
Discussion
We have designed and implemented a powerful quantitative high-throughput assay for PCNA ubiquitination, 
a key early event in DNA damage tolerance processes (reviewed in1–4,8). The system is an in vitro reconstituted 
ubiquitination reaction cascade, based on the highly sensitive Alpha proximity-based luminescence assay sys-
tem (Fig. 1a,b), with reliability confirmed by Western blot analysis (Figs 1c and 2). In the Alpha system, upon 
high-energy irradiation at 680 nm, a photosensitizer, phthalocyanine, embedded in the Alpha donor beads con-
verts ambient ground-state oxygen to an excited singlet state (distinct from the far more reactive oxygen radical). 
Singlet oxygen diffuses away and reacts with a thioxene derivative in the Alpha acceptor beads (within a practical 
range of ~200 nm), producing a chemiluminescent emission that then excites fluors also present in the acceptor 
beads, yielding fluorescence detected by a photomultiplier tube. There are two general variants of the Alpha assay, 
the so-called AlphaScreen and AlphaLISA assays, differing only in the dyes downstream of thioxene in the for-
mulation of the acceptor beads (anthracene and rubrene for AlphaScreen and a europium chelate for AlphaLISA), 
yielding different emission spectra maxima (520–620 nm for AlphaScreen or 615 nm for AlphaLISA acceptor 
beads), with all other aspects of the Alpha assay variants being the same. We found no difference in performance 
between the two variants in our system, where there are no components, as in serum or plasma samples, that 
might interfere with the AlphaScreen emission.
Screening for modulators of PCNA ubiquitination in a reconstituted system (consisting of the necessary and 
sufficient protein components of the cascade: RFC, Uba1, Rad6, Rad18, PCNA, and ubiquitin), we identified 
EGCG (structure in Fig. 6) as a potent inhibitor of ubiquitination (Fig. 2a,b). EGCG is a plant secondary metabo-
lite, the most abundant polyphenol in green tea and thought to be its primary health-promoting agent. EGCG can 
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Figure 3. Catechin gallates, alkyl gallates, and myricetin inhibit Uba1~ubiquitin thioester formation.  
(a) Representative Western blots showing that EGCG inhibits Uba1~ubiquitin thioester formation when 
preincubated with Uba1 before adding ubiquitin, but not when preincubated with ubiquitin first, while Myr inhibits 
Uba1~ubiquitin thioester in both cases. Final compound concentrations were 10 μM for EGCG or 50 μM for Myr 
(with DMSO alone as control and a DMSO concentration of 2% in all cases). Following preincubation, reactions were 
allowed to proceed for 2 h with ubiquitin, Uba1, and ATP. Comparison of results in the absence to presence of DTT 
as reducing agent confirms that the conjugation is through the reducible thioester. (b) Dose–response for relative 
% Uba1~ubiquitin thioester formation with increasing concentrations of each compound, plotted both linearly 
and semi-logarithmically (inset), with a DMSO concentration of 2% in all cases. Data represent mean ± SD for 3–4 
independent experiments, as indicated along with IC50 values for each case in Table 1. Each value was normalized on 
a gel-by-gel basis to the parallel positive control (DMSO alone with ATP) level of Uba1~ubiquitin thioester conjugate 
formed in each case and from quantitation of silver-stained SDS-polyacrylamide gels of reaction samples without 
DTT. (c) Relative % Uba1~ubiquitin thioester formation for compounds with no inhibitory activity even at 500 μM, 
with a DMSO concentration of 2% in all cases. Data represent mean and SD for four independent experiments.  
(d) EGCG does not inhibit formation of the Rad6~ubiquitin thioester conjugate resulting from transfer of ubiquitin 
from already formed Uba1~ubiquitin. The assay, with a DMSO concentration of 2% in all cases, and quantitation 
were done analogously to those for the Uba1~ubiquitin thioester formation experiments and are described in 
Methods. Data represent mean and SD for four independent experiments.
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bind and affect the activities of various proteins, with different degrees of potency, as well as function alternately 
as an antioxidant or a prooxidant; the compound possesses cytostatic and cytotoxic activity, can potentiate the 
effects of other treatments, and can reverse drug resistance in cells (reviewed in in9–30). Intriguingly, a defined 
green tea extract formulation (known as “sinecatechins”), composed of EGCG as the single largest component, is 
a United States Food and Drug Administration-approved topical treatment for human papillomavirus pathogene-
sis (reviewed in39), a process that is absolutely dependent on ubiquitination and degradation of p53, pRb, IκB, and 
other proteins involved in cell cycle checkpoint control (reviewed in40,41) and involves a virus-induced replication 
stress response hijacked for viral replication (reviewed in42).
We found that EGCG abrogates formation of the Uba1~ubiquitin thioester conjugate (Fig. 3a,b), but not 
formation of the Rad6~ubiquitin thioester conjugate resulting from transfer of the ubiquitin moiety from already 
formed Uba1~ubiquitin (Fig. 3d). The two most obvious possible mechanisms for inhibition of Uba1~ubiquitin 
thioester formation are that EGCG directly targets Uba1, possibly by binding to its active site, or that EGCG 
directly targets ubiquitin in such a way that it cannot be charged onto Uba1. The former possibility—that 
EGCG directly binds and thus inhibits Uba1—is far more likely. We determined that EGCG binds Uba1 by 
ligand-detected 1H NMR methods (Fig. 4) with an approximated Kd in a range similar to the IC50 values for 
inhibition of PCNA ubiquitination and Uba1–ubiquitin thioester formation by EGCG, strongly suggesting that 
it is the direct binding of Uba1 that accounts for the inhibitory activity. Furthermore, preincubation of Uba1 
alone with EGCG prior to addition of the other reaction components (ATP and ubiquitin) of the Uba1~ubiquitin 
Figure 4. NMR reveals that EGCG directly binds Uba1. (a) Aromatic 1H NMR region of EGCG in the presence 
of Uba1 (red) and without protein (black). (b) STD NMR spectrum recorded for EGCG in the presence of 
Uba1, aromatic region. (c) TrNOE experiment: no crosspeaks are present in the EGCG control experiment 
(left), while several crosspeaks appeared in the presence of Uba1 (negative NOE due to an equilibrium between 
the free and the bound state of EGCG). The data suggest a Kd in the range of high nM to low μM, as discussed in 
Results.
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Figure 5. Catechin gallates, alkyl gallates, and myricetin reduce cell viability in a manner protected by 
overexpression of Uba1 or ubiquitin in cells and EGCG inhibits global cellular ubiquitination. (a) Dose–
response for effects on HEK 293 cell survival after 24-h treatment with each compound relative to parallel 
untreated controls by the Alamar Blue (resazurin) assay. Data represent mean ± SD for 4–6 independent 
experiments (as indicated along with IC50 values for each case in Table 1), plotted both linearly and semi-
logarithmically (inset), with a DMSO concentration of 2% in all cases. (b) Overexpression of Uba1 or ubiquitin 
reduces sensitivity of cells to the cytostatic/cytotoxic effects of the compounds that also have in vitro activity 
against PCNA ubiquitination and Uba1~ubiquitin thioester formation (Figs 2b and 3b) but not those without 
activity (Figs 2c and 3c). Data represent mean and SD for % cell survival relative to parallel controls (DMSO 
alone) for three independent experiments, with a DMSO concentration of 2% in all cases. Higher survival 
values following compound treatment between Uba1- or ubiquitin-overexpressing HEK 293 cells compared 
to the corresponding empty vector-transfected control cells after 24-h compound treatment are indicated 
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thioester formation results in inhibition of the reaction, while preincubation of ubiquitin alone with EGCG does 
not (Fig. 3a). This implies that ATP and/or ubiquitin compete effectively with EGCG for binding to Uba1, and so 
EGCG may bind the ATP- or ubiquitin-binding site of Uba1.
EGCG has been previously shown to inhibit the autoubiquitination activity of the E3 ubiquitin ligase 
TRAF643,44, although, while EGCG does appear to bind TRAF644, the reduced TRAF6 ubiquitination observed 
with treatment in the published functional experiments could also be the result of upstream inhibition of Uba1 
and not necessarily TRAF6 directly. TRAF6, like Rad18, contains a so-called really interesting new gene (RING) 
zinc finger domain, thought to be involved in protein–protein interactions. We have no evidence thus far that 
EGCG directly inhibits Rad18. There are over 600 E3 ligases encoded by the human genome, the vast majority of 
them of the RING type, which display great structural diversity, particularly outside of the RING domain itself 
and in the substrate-binding domain (reviewed in45,46). Our results instead suggest that EGCG inhibits ubiquiti-
nation at the level of Uba1. It is worth noting, however, that EGCG and other catechin galloyl esters like ECG also 
obstruct another component of the overall ubiquitin–proteasome system: they appear to acylate and irreversibly 
inhibit the proteasome47,48, with a mechanism similar to that first described for the Streptomyces metabolite lacta-
cystin, whose elucidation helped establish that the proteasome is an N-terminal threonine protease49.
Uba1 has been proposed as a target for treatment of cancers and other pathological states linked to detrimen-
tal levels of ubiquitin–proteasome activity and other ubiquitination-dependent activities (reviewed in31–33). The 
overall approach of intervening therapeutically in the ubiquitin–proteasome pathway has been most dramatically 
validated by the success of the proteasome inhibitor bortezomib (Velcade) in the treatment of multiple myeloma. 
However, investigations to validate Uba1 itself as a drug target are still few in number. Notably, the pyrazolidines 
PYR-4150 and PYZD-440951 and the adenosine sulfamate TAK-243 (formerly known as MLN7243)52 have been 
found to inhibit Uba1 and appear to have promising therapeutic potential. TAK-243 is a potent mechanism-based 
inhibitor of the charging of Uba1 with ubiquitin that acts by forming a stable covalent adduct with the C-terminal 
carboxylate of ubiquitin, its direct target. TAK-243 and related reactive adenosine derivatives also likewise indi-
rectly inhibit other ubiquitin-like protein-activating enzymes to varying degrees52–55. In contrast, although con-
siderably less potent than TAK-243 (or EGCG and myricetin), PYR-41 appears to directly inactivate Uba1 itself 
rather than ubiquitin50, as does EGCG. TAK-243 and PYR-41 also differ in some of their biological effects56. A few 
other synthetic molecules57,58, natural products59–61, and modified ubiquitin derivatives62 have also been shown 
to inhibit Uba1.
In addition to being the likely EGCG target relevant to ubiquitination, Uba1 may account for part of EGCG’s 
overall cellular effects, given the broad importance of ubiquitination in cells. We found that overexpression of 
Uba1 in cells reduces EGCG’s cytostatic and cytotoxic effects (Fig. 5b), consistent with Uba1 being a major intra-
cellular EGCG-binding protein in the cell. This is most likely the result of titration of free EGCG by higher Uba1 
concentrations in the cell with overexpression. Overexpression of a compound-binding protein and evaluating 
whether sensitivity of cells is reduced to the compound’s effects or not has become an established approach to 
the confirmation of biological relevance of that putative target in explaining the compound’s cellular effects63–65. 
We also observed such a protective effect with overexpression of ubiquitin (Fig. 5b), further suggesting that the 
ubiquitination pathway is being targeted in the cell, and this is also still consistent with the hypothesis that Uba1 is 
the direct target of EGCG relevant to ubiquitination. The productive reaction in formation of the Uba1~ubiquitin 
thioester conjugate is trimolecular (involving Uba1 as covalent catalyst and ubiquitin and ATP as substrates), 
and overexpression of a binding partner of the direct target could also be protective if EGCG binds the target 
competitively with that additional component. The protective effects of Uba1 or ubiquitin overexpression are 
specific for EGCG and its biochemically active analogues, since neither of these manipulations affects sensitivity 
of cells to inactive analogues or to puromycin, a well-characterized protein synthesis inhibitor employed here as 
a representative unrelated cytotoxic agent (Fig. 5b).
with an asterisk (p < 0.003 in all cases by unpaired two-tailed Student’s t-tests). Treatment concentrations 
were at the IC50 values initially calculated for each compound shown in Table 1 from the data in (a), as well as 
1 μM and 2 μM for puromycin—denoted as “Puro (1)” and “Puro (2),” respectively—to evaluate effects of an 
unrelated cytotoxic agent. Note: EC, Cat, Myr, and DM all exhibited only very weak activity at 500 μM in the 
cell viability experiments in (a), and we were not able to test over high enough concentration range for proper 
determination of their IC50 values. However, of these four compounds, we chose to still examine whether Uba1 
and/or ubiquitin overexpression affected cell survival for Myr at 3 mM and DM at 650 μM (corresponding to 
their crudely guesstimated IC50 values), respectively, because Myr and DM had in vitro activity (Figs 2b and 3b), 
whereas EC and Cat did not (Figs 2c and 3c). Western blots of lysates from cells transfected with empty vector 
control, FLAG-ubiquitin-expressing, or FLAG-Uba1-expressing vector probed with anti-FLAG antibody, then 
stripped and probed with an anti-DNA polymerase δ catalytic subunit antibody as a loading control. The graph 
at right shows that Uba1 or ubiquitin overexpression by themselves had no effect on cell number in the parallel 
control cells in DMSO alone (mean and SD for three independent experiments), expressed as resorufin product 
signal in arbitrary fluorescence units (AFU) resulting from the metabolic reduction of resazurin in the assay. 
OE = overexpression. (c) Representative Western blot showing inhibition of global ubiquitination by EGCG 
in HEK 293 cells. Cells were treated with EGCG at 250 μM and 500 μM (with DMSO alone as control and a 
DMSO concentration of 1% in all cases) for 30 min, then MG132 was added to 50 μM, and cells were incubated 
for another 30 min, for a total EGCG treatment time of 1 h. Equivalent loadings of total protein from whole-
cell lysates were subjected to Western blot analysis with anti-ubiquitin antibody and then with anti-β-tubulin 
antibody as a housekeeping protein loading control.
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Furthermore, we found that EGCG inhibited global ubiquitination in cells (Fig. 5c). A previous study has 
shown that EGCG treatment results in upregulation of the expression of the E3 ligase RNF216 and thus increased 
ubiquitination and degradation of one of its substrates, the Toll-like receptor 466. However, this work was con-
ducted in macrophages at a relatively low concentration of EGCG with long treatment duration, conditions that 
may preclude inhibition of Uba1 in the cells (particularly since, with a single treatment over longer time scales, 
EGCG would become extensively degraded and metabolized to simpler products), but which results in increased 
expression of RNF216 and so enhanced ubiquitination of its specific substrates.
EGCG and related polyphenols are interesting compounds with medicinally important promise, awareness 
of which may further encourage the healthful and civilized practice of green tea consumption—to quote the 
Japanese scholar Okakura Kakuzō67: “Tea began as a medicine and grew into a beverage.” While inhibition of 
Uba1 and ubiquitination may account for part of EGCG’s overall activity in cells, EGCG clearly inhibits various 
other cellular pathways as well, some no doubt involved in its aggregate health-beneficial effects. Pleiotropic 
Figure 6. Structure–activity relationships for inhibition of PCNA ubiquitination, Uba1~ubiquitin thioester 
formation, and viability of normal, Uba1-overexpressing, and ubiquitin-overexpressing cells. More detailed 
information is contained in Figs 2, 3 and 5 and Table 1. OE = overexpression; N/A = not applicable.
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activity profiles are not uncommon for bioactive small molecules, and often it is indeed the felicitous combination 
of multiple targets inhibited that is the basis of preventive or therapeutic efficacy of a drug. Nonetheless, SAR 
investigations may clear paths toward the development of more selective compounds with improved activity pro-
files and greater utility. While the “co-evolution” of natural products with proteins means that they intrinsically 
have favorable protein-binding properties, it can also present challenges in terms of selectivity between targets, as 
many bind conserved motifs in proteins. However, generation of structures derived from or inspired by specific 
natural products, synthetically or semisynthetically, could improve selectivity for one protein over another. Such 
efforts could be guided by comparative SAR studies across different systems.
We tested analogues of EGCG differing in constitution and stereochemistry, and an informative multi-assay 
SAR picture has emerged (Figs 2, 3 and 5 and Table 1; summarized with structures in Fig. 6). The EGCG-related 
molecules showed a divergence of different SAR profiles, with the comparative activity patterns falling into the 
following groupings: (1) catechin gallates (EGCG and ECG), which show very good correspondence between 
activity profiles in the different assays, being inhibitory in the in vitro biochemical (PCNA ubiquitination and 
Uba1~ubiquitin thioester formation) and cellular assays (cell viability—with negative effects mitigated by over-
expression of Uba1 or ubiquitin); (2) simple unesterified catechins, which display no (EC and Cat) or weak (EGC) 
activity in the assays; (3) longer-chain alkyl gallates (OG and DG), which are active in all the assays, with their 
cytotoxic effects being mitigated in cells by overexpression of Uba1 or ubiquitin (while both the short-chain alkyl 
gallate PG and free GA itself are inactive in the biochemical assays, and their negative effects on cell viability are 
unaffected by Uba1 or ubiquitin overexpression); or (4) Myr and DM, which have potent (Myr) or weak (DM) 
activity in the biochemical assays and only weak activity against cell survival, with Uba1 or ubiquitin overexpres-
sion reducing the sensitivity of cells to these compounds.
All the compounds that exhibited activity in the in vitro PCNA ubiquitination and Uba1~ubiquitin thioester 
formation experiments also had cytostatic/cytotoxic effects that were mitigated with overexpression of Uba1, 
ubiquitin, or both (Fig. 5b). This suggests that all the bioactive compounds were also binding Uba1 and/or ubiq-
uitin in the cell and that inhibition of ubiquitination at that level is relevant to the physiological activity of all these 
compounds. However, it is possible and indeed likely that the different structural classes of bioactive compounds, 
while each targeting some site on Uba1 and/or ubiquitin itself are also mechanistically distinct.
The potent inhibitory activity of the catechin gallates against the ubiquitination cascade appears to require a 
composite structure of both catechin and galloyl moieties. EGCG is an ester of EGC and GA, while ECG is an 
ester of EC and GA. Free EGC itself has weak activity in the biochemical assays (Figs 2b and 3b), while free GA is 
inactive, as is free EC (Figs 2c and 3c). It is known that galloylation also strongly influences various other bioactiv-
ities of catechins and other natural products (reviewed in68). Furthermore, the 5′-OH of the B ring on the catechin 
skeleton of EGCG seems to play a role in activity, possibly through hydrogen bonding with Uba1, since ECG, 
which lacks this hydroxyl group, has slightly diminished biochemical activity (see Fig. 6). Similarly, free EGC by 
itself still possesses some activity, while EC does not, again demonstrating the significance of the B-ring 5′-OH.
The mechanism of action of the longer-chain alkyl gallates (OG and DG) in inhibiting ubiquitination may 
be distinct from that of the catechin gallates and Myr (and its formal hydrogenation product DM). OG and DG, 
Compound
IC50 for inhibition of 
PCNA ubiquitination
IC50 for inhibition 
of Uba1~ubiquitin 
thioester formation
IC50 for inhibition of cell 
survival
Effect of Uba1 
overexpression on 
cell survival
Effect of ubiquitin 
overexpression on 
cell survival
EGCG 0.2280 μM (SE = 0.03419; CI: 0.1714–0.3192; n = 7)
1.632 μM (SE = 0.4580; 
CI: 0.8348–3.451; n = 4)
220.2 μM (SE = 18.90; CI: 
187.4–263.5; n = 6) Protects Protects
ECG 0.5369 μM (SE = 0.09460; CI: 0.3750–0.8431; n = 4)
4.223 μM (SE = 2.161; 
CI: 1.263–13.77; n = 6)
261.7 μM (SE = 33.88; CI: 
206.2–353.4; n = 6) Protects Protects
EGC 43.28 μM (SE = 22.81; CI: 16.08–129.0; n = 4)
7.584 μM (SE = 3.869; 
CI: 2.927–20.67; n = 7)
175.7 μM (SE = 18.05; CI: 
144.0–218.5; n = 4) Does not protect Does not protect
EC >500 μM (n = 3) >500 μM (n = 4) >500 μM (n = 4) N/A N/A
Cat >500 μM (n = 3) >500 μM (n = 4) >500 μM (n = 4) N/A N/A
GA >500 μM (n = 3) >500 μM (n = 4) 240.7 μM (SE = 18.12; CI: 206.6–280.3: n = 4) Does not protect Does not protect
PG >500 μM (n = 3) >500 μM (n = 4) 176.3 μM (SE = 23.55; CI: 135.8–240.4; n = 4) Does not protect Does not protect
OG 10.32 μM (SE = 6.406; CI: 3.182–40.09; n = 4)
80.60 μM (SE = 33.90; 
CI: 34.81–405.1; n = 4)
38.70 μM (SE = 3.106; CI: 
32.72–45.46; n = 4) Protects Protects
DG 1.633 μM (SE = 0.3117; CI: 1.048–2.670; n = 5)
35.00 μM (SE = 25.11; 
CI: 6.288–533.1; n = 4)
33.46 μM (SE = 3.247; CI: 
27.15–40.83; n = 4) Does not protect Protects
Myr 1.213 μM (SE = 0.2083; CI: 0.8755–4.201; n = 5)
0.7207 μM (SE = 0.4970; 
CI: 0.1766–2.680; n = 5) >500 μM (n = 6) Protects Protects
DM 66.43 μM (SE = 38.92; CI: 27.21–180.9; n = 3)
14.27 μM (SE = 3.140; 
CI: 5.927–22.18; n = 3) >500 μM (n = 6) Does not protect Protects
Table 1. Half-maximal inhibitory concentration (IC50) values for compounds against PCNA ubiquitination and 
Uba1~ubiquitin thioester formation and effects on viability of normal, Uba1-overexpressing, and ubiquitin-
overexpressing cells. All IC50 values, standard errors, and 95% confidence intervals listed were calculated by 
nonlinear regression with GraphPad Prism software. The effects of compounds on cell survival in Uba1 and 
ubiquitin-overexpressing cells relative to empty vector-transfected control cells are also shown. SE = standard 
error; CI = 95% confidence interval; n = number of independent experiments; N/A = not applicable.
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both esters of n-alkanols (of length C8 and C12, respectively) and GA, are amphiphiles with a polar “head” and 
straight-chain hydrophobic “tail.” Even though the fact that they are active against the PCNA ubiquitination 
cascade at relatively low concentrations suggests some element of specific recognition involved, they may have 
detergent-like local-denaturing effects upon binding, consistent with the increasing inhibitory activity in the 
biochemical assays with longer alkyl chain, with the order of potency being DG > OG ≫ PG (Figs 2b,c, 3b,c and 
Table 1). They exhibit high inherent variability in the biochemical experiments, and DG, in particular, displays 
large divergence in potency between the PCNA ubiquitination and Uba1~ubiquitin thioester formation assays 
(Table 1). These results suggest that, unlike the catechin gallates and Myr, the alkyl gallates may weakly inhibit 
multiple components of the cascade in the reconstituted PCNA ubiquitination system and without a single spe-
cific recognition interaction, with less of the more straightforward drug-like behavior against Uba1 exhibited by 
the other bioactive compound classes.
Myr likely also has a unique mechanism of action. Myr and DM do not possess a galloyl moiety, as do the cat-
echin gallates and alkyl gallates. Myr potently inhibits thioester formation whether preincubated with Uba1 alone 
or ubiquitin alone before addition of other reaction components, whereas EGCG inhibits when preincubated 
with Uba1 but not ubiquitin (Fig. 3a). These results suggest either that Myr binds Uba1 non-competitively with 
ATP and ubiquitin or that Myr binds ubiquitin directly, in either case inhibiting formation of the Uba1~ubiquitin 
thioester conjugate by a mechanism that is distinct from EGCG. Furthermore, unlike all the other molecules 
examined in this study, Myr and DM are both ketone carbonyl compounds, and this may be key to their activity.
The strong activity of Myr may be tied to its Michael acceptor (α,β-unsaturated carbonyl) functionality, a 
potentially reactive electrophile susceptible to attack by nucleophilic groups on proteins and other molecules. In 
the Michael addition reaction, a nucleophile adds to the electrophilic β carbon of the α,β-unsaturated carbonyl. 
In such a mechanism for Myr, the carbon labeled “β” in Fig. 6 would be the site of attack by a nucleophile on Uba1 
(such as the side-chain thiol of its active-site cysteine, normally involved in reaction with ubiquitin to form the 
Uba1~ubiquitin thioester adduct). DM, which lacks an α,β-unsaturated carbonyl, is much more weakly active 
against ubiquitination and Uba1~ubiquitin thioester formation than Myr, consistent with such a mechanism. 
Since the Michael reaction is often irreversible, we tested whether Myr irreversibly inhibits Uba1 and/or ubiq-
uitin function or not. We found that Myr, like EGCG, appears to inhibit ubiquitination in a reversible manner 
(Fig. 2d). While, on the face of it, this may make such a mechanism seem less probable, a covalent though revers-
ible reaction is still not unlikely to be involved. The electronic and steric effects of the substitution pattern on the 
α and β carbons, as well as the nature of the incoming nucleophile on the target, may make Michael addition to 
Myr reversible through β elimination. Indeed, such chemical parameters are known to influence reactivity and 
reversibility in Michael acceptors, with numerous examples of reversible bioactive Michael acceptor-containing 
compounds in the literature (reviewed in69,70).
The Michael reaction is a 1,4-addition (conjugate addition) reaction, where the incoming nucleophile adds 
to the β carbon of the α,β-unsaturated carbonyl. Another reaction typical of these systems is 1,2-addition (direct 
addition), where the nucleophile reacts with the carbonyl carbon instead of the β carbon. (Direct addition is, in 
fact, kinetically, though not thermodynamically, favored over conjugate addition.) It is generally reversible for 
weakly basic nucleophiles, such as thiols, alcohols, and amines, the most common nucleophiles present in pro-
teins. Therefore, a reversible covalent protein–small molecule species could also be the result of a direct addition 
of a protein nucleophile to the ketone carbonyl on Myr, a reaction also be available to DM.
Both reversible Michael addition and direct addition are possibilities to explain why the α,β-unsaturated 
carbonyl appears important for activity in Myr, and these candidate mechanisms are not mutually exclusive. In 
contrast, in DM, only direct addition to the ketone is possible, which could conceivably explain its weak residual 
activity. This is consistent with the observation that Cat, which differs from DM only in lacking the ketone, is 
entirely inactive. Thus, both conjugate and direct addition may be involved in Myr’s inhibitory activity, with con-
jugate addition likely playing the larger role. However, it is not possible to exclude at this point purely structural 
explanations that do not involve any covalent reaction. The compounds differ geometrically in addition to elec-
tronically: Myr possesses a planar α,β-unsaturated system, while DM has tetrahedral α and β centers. Therefore, 
Myr’s mechanism of action could involve reversible covalent reaction(s), non-covalent inhibitory interaction 
between small molecule and protein, or a combination of these non-mutually exclusive mechanisms.
Green tea polyphenols, particularly EGCG, have widely acknowledged potential as preventive or therapeutic 
agents against a range of cancers and other disease states. Inhibition of Uba1 and ubiquitination, recognized as 
promising loci for therapeutic intervention in many of the same diseases, may account for part of EGCG’s overall 
biological effects, and so the present work may help lead to a better understanding EGCG’s health-beneficial 
properties. Moreover, the fact that EGCG and its analogues fall into distinct mechanistic subclasses that are 
rather cleanly correlated to structure opens up exciting possibilities for future research. Each series of bioactive 
small molecule identified represents a different first-in-class type of chemical modulator of ubiquitination, a 
hierarchical cascade of reactions that has drawn great interest from both the basic research and drug discovery 
communities. Improved specificity and selectivity may arise from assessment of further natural, semisynthetic, 
or synthetic congeners of the pharmacophore types delineated in the present study, yielding valuable therapeutic 
drug leads and tools from these different structural and mechanistic sets of molecules.
Methods
Materials. His-tagged human Uba1 in the pET3a bacterial expression vector71 (Addgene Cat#63571) was 
expressed in the E. coli strain BL21(DE3) and purified with Ni-NTA agarose beads (Macherey-Nagel). Purified S. 
cerevisiae RFC (all 5 subunits coexpressed in the E. coli strain BL21-Gold(DE3)), human Rad6B–Rad18 complex 
(coexpressed as in S. cerevisiae strain BJ5464), FLAG-tagged human Rad6B, FLAG-tagged human PCNA, and 
glutathione-S-transferase (GST)-tagged human ubiquitin were prepared as previously described34,35,72,73. Proteins 
that were expressed as GST fusions had the GST moiety removed with PreScission protease (GE Healthcare), with 
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the exception of the GST-ubiquitin used in GST-based detection experiments. Concentrations of purified pro-
teins were determined by measuring ultraviolet light absorbance at 280 nm in a spectrophotometer and applying 
the Beer-Lambert law with the calculated extinction coefficient for each protein.
Biotinylated human ubiquitin was purchased from Boston Biochemicals/R&D Systems (UB-570). Nicked 
DNA for PCNA loading was prepared by incubating purified pUC19 plasmid with Nt.BstNBI (New England 
Biolabs) at 55 °C overnight. Streptavidin donor and anti-FLAG acceptor AlphaScreen and AlphaLISA beads were 
purchased from PerkinElmer. Anti-FLAG M2 monoclonal antibody conjugated to horseradish peroxidase (HRP) 
was purchased from Sigma-Aldrich, HRP-conjugated anti-GST antibody conjugate was from GE Healthcare, and 
anti-DNA polymerase δ catalytic subunit antibody (A-9) and anti-β-tubulin monoclonal antibody (D-10) was 
from Santa Cruz Biotechnology.
EGCG and related molecules utilized in this study were from an in-house compound collection at Avicor or 
purchased from Selleck Chemicals or Adooq Bioscience. All small molecules were dissolved in dimethyl sulfoxide 
(DMSO) to make concentrated stock solutions and further serially diluted in DMSO to appropriate concentra-
tions, as needed, before use in experiments. Compounds, both as solids and short-term DMSO stock solutions, 
were stored desiccated until use. Periodic analysis by liquid chromatography–mass spectrometry confirmed sta-
ble structural integrity of all of the compounds, without decomposition, both as solids and in DMSO.
PCNA ubiquitination. The PCNA loading and ubiquitination cascade was reconstituted in 96-well white 
round-bottom polypropylene plates (Greiner) in a buffer consisting of 40 mM Tris-HCl, pH 7.5, 8 mM MgCl2, and 
10% glycerol with 2.5 nM nicked circular pUC19, 50 nM RFC, 50 nM Uba1, 250 nM Rad6–Rad18 dimer, 50 nM 
FLAG-PCNA, and 250 nM biotin-ubiquitin (final concentrations). Compounds were added to the samples, with 
preincubation for 15 min at 25 °C before addition of ATP to a final concentration of 2 mM (to initiate the reaction 
cascade), followed by incubation for 2 h at 25 °C. The reactions were then terminated by addition of EDTA to 
20 mM for Alpha assays or Laemmli sample buffer for Western blot analyses. For Alpha assays, reaction mix-
tures were diluted in buffer containing streptavidin-conjugated donor beads and anti-FLAG antibody-conjugated 
acceptor beads in opaque white microplates under low-light conditions, as recommended by the Alpha bead 
manufacturer, PerkinElmer. The plates were read on a Tecan Spark microplate reader at 23 °C. For Western blot 
analyses, FLAG-PCNA was detected with anti-FLAG antibody, and quantitations from the Western blot images 
was performed with NIH ImageJ software74 and then analyzed with GraphPad Prism software.
For reversibility, 7.5 μM Uba1 was incubated with 30 µM of EGCG or Myr (or DMSO carrier solvent alone as 
a control) for 2 h at 25 °C. Samples were then transferred to YM-30 Microcon centrifugal concentrators (Merck 
Millipore), diluted in buffer (40 mM Tris-HCl, pH 7.5, 8 mM MgCl2, and 10% glycerol), then serially centrifuged 
with additions of buffer to the remaining retentate between each spin, for final dilutions of compounds to <0.05% 
of original concentrations. The resulting samples were then tested in PCNA ubiquitination reactions.
Uba1~ubiquitin thioester formation. The assay was carried out in a buffer consisting of 40 mM 
Tris-HCl, pH 7.5, 8 mM MgCl2, and 10% glycerol with final concentrations of Uba1 and GST-ubiquitin of 
150 nM and 450 nM, respectively. Following preincubation of Uba1 alone with compounds for 15 min at 25 °C, 
GST-ubiquitin and ATP (the latter to 2 mM) were added, and the samples were incubated for 2 h at 25 °C. 
Laemmli sample buffer with or without dithiothreitol (DTT) as reducing agent was added into each reaction, 
and samples were resolved on 8% sodium dodecyl sulfate (SDS)-polyacrylamide gels, with visualization by sil-
ver staining or Western blot analysis with anti-GST antibody. For silver staining, gels were fixed in 40% metha-
nol and 10% acetic acid for 20 min, sensitized for 1 min with 0.02% sodium thiosulfate, stained for 10 min with 
0.1% silver nitrate in 0.01% formaldehyde, and developed in 3% sodium carbonate and 0.05% formaldehyde. 
Quantitative determination of the extent of Uba1~ubiquitin thioester formation was carried out from scanned 
images of silver-stained gels of reaction samples without DTT with NIH ImageJ software74 followed by analysis 
with GraphPad Prism software. GST-ubiquitin rather than untagged ubiquitin was used because the greater 
distance separation of free Uba1 and Uba1~ubiquitin bands on the non-reducing SDS–polyacrylamide gels 
allowed for clearer resolution of the Uba1~ubiquitin thioester conjugate, while still displaying similar kinetics 
and levels of thioester formation.
Rad6~ubiquitin thioester formation. The overall reaction was conducted in two separate steps: initial 
reaction of Uba1 with ubiquitin in the absence of compound, then mixing with Rad6 with compound to eval-
uate transfer of ubiquitin from already formed Uba1~ubiquitin to Rad6. The first reaction was conducted with 
300 nM Uba1, 1 μM GST-ubiquitin, and 2 mM ATP in a buffer of 40 mM Tris-HCl, pH 7.5, 8 mM MgCl2, and 
10% glycerol for 30 min at 25 °C to allow for charging of Uba1 with GST-ubiquitin incubations. Separately, Rad6 
(1 μM) was preincubated with EGCG for 15 min at 25 °C, also in a buffer of 40 mM Tris-HCl, pH 7.5, 8 mM 
MgCl2, and 10% glycerol, and then the precharged Uba1 from the first reaction was added as an equal volume 
to the compound-treated Rad6 samples (for final concentrations of Uba1, Rad6, and GST-ubiquitin of 150 nM, 
500 nM, and 500 nM, respectively), with incubation of the mixture for another 15 min at 25 °C to allow for trans-
fer of ubiquitin from Uba1 to Rad6. The samples were then subjected to SDS-polyacrylamide gel electrophoresis 
under non-reducing conditions, silver staining, and quantitation of scanned images, as described above for the 
silver-staining-based Uba1~ubiquitin thioester formation assay.
NMR analysis of EGCG–Uba1 binding. NMR spectra were acquired with a Bruker Avance 600 MHz 
spectrometer equipped with a 5 mm z-gradient CP-TCI triple-resonance cryoprobe at 303 K. EGCG and Uba1 
were dissolved in 20 mM phosphate-buffered saline at pH 7.4 (90% H2O, 10% D2O), containing 150 mM NaCl 
and 0.02% NaN3. In order to prevent EGCG oxidation, 1 mM tris(2-carboxyethyl)phosphine was added to the 
solutions. EGCG and Uba1 concentrations were 400 μM and 4 μM, respectively. All the spectra were acquired 
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with excitation sculpting solvent suppression pulse scheme. In STD experiments, 40 equally spaced 50 ms 
Gaussian-shaped pulses were used for the selective saturation of the protein, thus the total saturation time was 
2 s. The on-resonance irradiation and the off-resonance saturation frequency were set at 0.86 ppm and 40.0 ppm, 
respectively. A total of 2k scans were collected for each pseudo 2D experiment. 2D NOESY experiments were 
acquired with 128 increments and a mixing time of 100 ms. As a control, all the experiments were repeated for a 
sample containing EGCG at the same concentration but in the absence of the protein.
Cell culture. For cellular experiments, HEK 293FT cells (a fast-growing SV40 large T antigen-transformed 
strain of HEK 293 cells designed for enhanced transgene expression in transient transfections) were grown in 
growth medium consisting of Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich), supplemented with 
10% fetal bovine serum (FBS; Gibco) in a humified cell culture incubator at 37 °C with 5% CO2.
Cell survival. HEK 293FT cells were evaluated for survival following compound treatments by the Alamar 
Blue (resazurin) assay. Cells were plated onto 96-well plates at 4.8 × 104 cells/well in 0.5% FBS-containing DMEM 
at 37 °C and 5% CO2. After 24 h, compounds were added. After 24-h treatment, resazurin was added to a final 
concentration of 0.12 mM. Following 4-h incubation, conversion to the resorufin product was measured (with 
excitation at 542 nm and emission at 590 nm) on a fluorescence plate reader.
Cell transfections. HEK 293FT cells (1.5 × 106) were plated onto 6-cm plates in 5 ml of DMEM with 10% 
FBS and allowed to grow for 24 h at 37 °C and 5% CO2. For transfections, 6 μg of plasmid DNA (empty vector con-
taining FLAG-tag sequence only, FLAG-Uba1, or FLAG-ubiquitin) and 10 μl of Lipofectamine 2000 were used for 
each plate. The DNA and the reagent were diluted separately in 500 μl of Opti-MEM (Gibco), and each was mixed 
by vortexing. After 5-min incubation, the two tubes were combined and incubated for another 20 min. Prior to 
adding the transfection solution to the cells, the medium was replaced with 4 ml of Opti-MEM. The transfec-
tion solution was then added dropwise. After 3-h incubation, the medium was changed to 0.5% FBS-containing 
DMEM, and the cells were plated for cell survival experiments, as above.
Cellular ubiquitination. HEK 293FT cells were plated in 6-well plates at 8 × 105 cells/well in DMEM with 
0.5% FBS. After 24 h at 37 °C and 5% CO2, EGCG was added; then 30 min later, MG132 was added to a concen-
tration of 50 μM, with incubation for another 30 min (for a total of 1-h EGCG treatment). Cells were harvested, 
and whole-cell lysates were prepared in RIPA lysis buffer containing protease inhibitor cocktail (SIGMAFAST 
from Sigma-Aldrich) and sonicated. Equivalent loadings of total protein for each treatment, as determined by 
Bradford assay of each extract sample, were subjected to electrophoresis on 8% SDS-polyacrylamide gels and 
Western blot analysis, probed with anti-ubiquitin antibody, then stripped and reprobed with anti-β-tubulin 
antibody.
Statistical analysis. Curve fitting and statistical analysis were performed with GraphPad Prism 8.0–8.2 
software. Quantitative data in graphs are presented as mean and standard deviation (SD).
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